Project Grant R43AI118180

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Sherlock Biosciences, Inc. a $298,948 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a power-free molecular diagnostic device for detecting Chlamydia trachomatis and Neisseria gonorrhoeae, the pathogens that cause the majority of sexually transmitted infections (STIs). The project aims to create an accurate, transportable, and easy-to-use at-home test that does not require...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...

This K23 career development award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports Dr. Lao-Tzu Allan-Blitz's research to develop and pilot a low-cost, point-of-care (POC) CRISPR-based assay for detecting Neisseria gonorrhoeae and molecular markers of antimicrobial resistance in resource-limited settings. The total funding is $195,480 over the 5-year award period from August 2024 to July...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $163,698 to Magic Lifescience, Inc. to develop a novel point-of-care (POC) molecular diagnostic assay for syphilis detection. The goal is to create a multiplexed genital ulcer disease (GUD) panel test that can rapidly and accurately diagnose syphilis, as well as other pathogens causing GUD, using giant magnetoresistive...

This $466,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop rapid and ultrasensitive aptamer-based detection technologies for the diagnosis of Treponema pallidum infections, the causative agent of syphilis. The project seeks to address the limitations of current syphilis diagnostic methods by developing aptamers that can specifically and sensitively detect T....

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Teardx, LLC will fund the development of a rapid, point-of-care diagnostic test to accurately detect ocular herpes simplex virus (HSV-1) infections. The project aims to create a user-friendly, minimally invasive sampling tool and assay that can be used by eye specialists and urgent care clinicians to quickly screen for active HSV-1 infections, which are a leading cause...

This $960,000 National Science Foundation project grant supports the development of a multiplexed plasmon-enhanced lateral flow assay for point-of-care detection of SARS-CoV-2 RNA and antigens. Funded under the NSF Engineering program (CFDA 47.041), the grantee, Washington University, will design, validate and build a novel diagnostic platform with sensitivity exceeding standard laboratory tests. Key deliverables include an ultrasensitive multiplexed lateral flow assay for simultaneous...

The National Science Foundation (NSF) awarded a $650,000 project grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to the University of Nevada, Reno to establish a point-of-care (POC) platform technology using smartphone-based time-resolved luminescence imaging and detection (STRIDE) enabled by manganese-doped semiconductor nanocrystals and artificial intelligence. This 1-year project will: (1) further develop the photophysics and optical properties of the...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $312,817 to Giner Inc., a small business R&D firm based in Massachusetts, to develop a point-of-care testing (POCT) instrument for highly sensitive and near-real-time measurement of oxytocin levels. The Phase I program will focus on improving and validating the company's novel electrochemical assay...

The National Institute of Justice awarded a $0.00 Project Grant to The Leland Stanford Junior University from January 2018 through December 2020 under the National Institute of Justice Research, Evaluation, and Development Project Grants program (CFDA 16.560). The grant funded the development of a confirmatory test for sperm in sexual assault samples using a microfluidic-integrated cell phone imaging system. Work included designing a chip to support ease of use, performance and manufacturability...